Psoriasis vaccine - Astralis/Pacira

Drug Profile

Psoriasis vaccine - Astralis/Pacira

Alternative Names: AS 210; Psoraxine; Second-generation Psoraxine

Latest Information Update: 11 Dec 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Astralis
  • Class Antipsoriatics; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Psoriasis

Most Recent Events

  • 11 Dec 2007 Suspended - Phase-II for Psoriasis in USA (Injection)
  • 22 Jun 2007 SkyePharma Inc. is now called Pacira Pharmaceuticals
  • 06 May 2005 Data presented at the 66th Annual Meeting of the Society for Investigative Dermatology (SID-2005) have been added to the adverse events and Skin Disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top